🧠AI AnalysisSavara Faces Critical FDA Review Date as Investors Weigh Regulatory Risk
Small-cap pharmaceutical firm Savara approaches a pivotal November 22 FDA regulatory milestone that could significantly impact its market valuation.
Topic: Savara
🧠AI Analysis